194 related articles for article (PubMed ID: 37115691)
21. Potential Effects of Hormone Therapy in Type 2 Idiopathic Macular Telangiectasia.
Wolf-Schnurrbusch UEK; Leung I; Sallo FB; Clemons TE; Chew EY; Bird AC; Peto T;
Ophthalmic Res; 2018; 60(1):38-42. PubMed ID: 28903123
[TBL] [Abstract][Full Text] [Related]
22. Multicolor imaging in macular telangiectasia-a comparison with fundus autofluorescence.
Govindahari V; Fraser-Bell S; Ayachit AG; Invernizzi A; Nair U; Nair DV; Lupidi M; Singh SR; Rajendran A; Zur D; Gallego-Pinazo R; Marco RD; Cagini C; Cozzi M; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2020 Nov; 258(11):2379-2387. PubMed ID: 32803329
[TBL] [Abstract][Full Text] [Related]
23. Retinal ganglion cells thinning in eyes with nonproliferative idiopathic macular telangiectasia type 2A.
Chhablani J; Rao HB; Begum VU; Jonnadulla GB; Goud A; Barteselli G
Invest Ophthalmol Vis Sci; 2015 Feb; 56(2):1416-22. PubMed ID: 25655800
[TBL] [Abstract][Full Text] [Related]
24. Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2.
Moir J; Amin SV; Khanna S; Komati R; Shaw LT; Dao D; Hariprasad SM; Skondra D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887197
[TBL] [Abstract][Full Text] [Related]
25. Overlap between telangiectasia and photoreceptor loss increases with progression of macular telangiectasia type 2.
Micevych PS; Lee HE; Fawzi AA
PLoS One; 2019; 14(10):e0224393. PubMed ID: 31658282
[TBL] [Abstract][Full Text] [Related]
26. Atypical bilateral presentation in idiopathic macular telangiectasia type 1.
Tapia Quijada HE; Mantolan Sarmiento C; Serrano García M; Betancor Caro N
Arch Soc Esp Oftalmol (Engl Ed); 2021 Nov; 96(11):602-606. PubMed ID: 34756283
[TBL] [Abstract][Full Text] [Related]
27. Demographic features of idiopathic macular telangiectasia in Korean patients.
Kim SH; Oh J; Ahn SE; Park CY; Oh JH
Korean J Ophthalmol; 2015 Jun; 29(3):155-9. PubMed ID: 26028942
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and Severity of Diabetic Retinopathy in Patients with Macular Telangiectasia Type 2.
van Romunde SHM; van der Sommen CM; Martinez Ciriano JP; Vingerling JR; Yzer S
Ophthalmol Retina; 2021 Oct; 5(10):999-1004. PubMed ID: 33444807
[TBL] [Abstract][Full Text] [Related]
29. Amniotic Membrane Enhances the Characteristics and Function of Stem Cell-Derived Retinal Pigment Epithelium Sheets by Inhibiting the Epithelial-Mesenchymal Transition.
Zhang S; Ye K; Gao G; Song X; Xu P; Zeng J; Xie B; Zheng D; He L; Ji J; Zhong X
Acta Biomater; 2022 Oct; 151():183-196. PubMed ID: 35933105
[TBL] [Abstract][Full Text] [Related]
30. Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography.
Spaide RF; Klancnik JM; Cooney MJ
JAMA Ophthalmol; 2015 Jan; 133(1):66-73. PubMed ID: 25317692
[TBL] [Abstract][Full Text] [Related]
31. Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8.
Heeren TFC; Chew EY; Clemons T; Fruttiger M; Balaskas K; Schwartz R; Egan CA; Charbel Issa P;
Ophthalmology; 2020 Nov; 127(11):1539-1548. PubMed ID: 32586743
[TBL] [Abstract][Full Text] [Related]
32. Functional relevance of macular telangiectasia (MacTel) area on multicolour imaging in type 2 MacTel.
Venkatesh R; Reddy NG; Agrawal S; Pereira A; Mutalik D; Mishra P; Yadav NK; Chhablani J
Eur J Ophthalmol; 2022 Jul; 32(4):2368-2374. PubMed ID: 34488467
[TBL] [Abstract][Full Text] [Related]
33. FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2 WITH AND WITHOUT DIABETES.
Sauer L; Vitale AS; Jacoby RS; Hart B; Bernstein PS
Retina; 2023 Sep; 43(9):1597-1607. PubMed ID: 37263186
[TBL] [Abstract][Full Text] [Related]
34. Imbalanced unfolded protein response signaling contributes to 1-deoxysphingolipid retinal toxicity.
Rosarda JD; Giles S; Harkins-Perry S; Mills EA; Friedlander M; Wiseman RL; Eade KT
Nat Commun; 2023 Jul; 14(1):4119. PubMed ID: 37433773
[TBL] [Abstract][Full Text] [Related]
35. Analysis of candidate genes for macular telangiectasia type 2.
Parmalee NL; Schubert C; Merriam JE; Allikmets K; Bird AC; Gillies MC; Peto T; Figueroa M; Friedlander M; Fruttiger M; Greenwood J; Moss SE; Smith LE; Toomes C; Inglehearn CF; Allikmets R
Mol Vis; 2010 Dec; 16():2718-26. PubMed ID: 21179236
[TBL] [Abstract][Full Text] [Related]
36. [Characteristics, multimodality imaging and treatment of macular telangiectasia type 2].
Cai Y; Shi X; Zhao MW; Li XX
Zhonghua Yan Ke Za Zhi; 2019 Jan; 55(1):68-73. PubMed ID: 30641677
[TBL] [Abstract][Full Text] [Related]
37. Choroidal vascularity index: an enhanced depth optical coherence tomography-based parameter to determine vascular status in patients with proliferative and non-proliferative macular telangiectasia.
Karasu B; Celebi ARC
Int Ophthalmol; 2021 Oct; 41(10):3505-3513. PubMed ID: 34181193
[TBL] [Abstract][Full Text] [Related]
38. Does size of telangiectasia on optical coherence tomography angiography influence vision in eyes with type 2 macular telangiectasia?
Kelkar AS; Kelkar JA; Tidke S; Agarwal A; Bolisetty M; Kelkar S
Indian J Ophthalmol; 2021 Dec; 69(12):3570-3576. PubMed ID: 34826997
[TBL] [Abstract][Full Text] [Related]
39. Retinal crystals in type 2 idiopathic macular telangiectasia.
Sallo FB; Leung I; Chung M; Wolf-Schnurrbusch UE; Dubra A; Williams DR; Clemons T; Pauleikhoff D; Bird AC; Peto T;
Ophthalmology; 2011 Dec; 118(12):2461-7. PubMed ID: 21839520
[TBL] [Abstract][Full Text] [Related]
40. Description of a patient cohort with Hereditary Sensory Neuropathy type 1 without retinal disease Macular Telangiectasia type 2 - implications for retinal screening in HSN1.
Rodrigues FG; Pipis M; Heeren TFC; Fruttiger M; Gantner M; Vermeirsch S; Okada M; Friedlander M; Reilly MM; Egan C
J Peripher Nerv Syst; 2022 Sep; 27(3):215-224. PubMed ID: 35837722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
